Cancer drug demand drives higher sales for AstraZeneca - Revenues from oncology products made up 43% of the company’s total ...

Astrazeneca has revealed a jump in revenue from cancer drugs amid rumours its boos is eyeing a listing across the pond. Total ...

AstraZeneca share price held steady this week after the company published strong financial results on Tuesday.

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

Virginia facility investment will be AstraZeneca’s largest yet. Maryland, Massachusetts, California, Indiana, Texas projects ...

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. By 2030, it expects to generate $80 billion in total revenues.

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca's strategic $50B investment promises to revolutionize U.S. medicine production with advanced manufacturing and ...

With the threat of tariffs looming for medicines imported to the United States, AstraZeneca has unveiled a plan to invest $50 ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...